Abstract
INTRODUCTION Apolipoprotein (APOE) ε4 and subjective cognitive decline (SCD) increase risk of Alzheimer’s disease. However, few studies have examined the relationship between SCD and APOE, especially using longitudinal data. The current study examined whether APOE is associated with the rate of cognitive change in SCD.
METHODS Linear mixed effects models examined the relationship between APOE status and cognitive change in older adults with SCD (SCD), normal controls (NC), and people with mild cognitive impairment (MCI).
RESULTS The presence of at least one ε2 allele in SCD and MCI results in cognitive change rates similar to a NC with the ε3ε3 genotype. Older SCD-ε4 individuals exhibited increased cognitive decline compared to all groups, including NC-ε4 and MCI-ε4.
DISCUSSION People with SCD with at least one ε4 allele will experience increased cognitive decline compared to cognitively healthy older adults and people with MCI. These findings have important implications for treatments and interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Morrison is supported by a postdoctoral fellowship from Canadian Institutes of Health Research, Funding Reference Number: MFE-176608. Dr. Kamal is supported by the Quebec Bioimaging Network and Fonds de Recherche du Quebec (FRQS) postdoctoral scholarships. Dr. Dadar reports receiving research funding from the Healthy Brains for Healthy Lives (HBHL), Alzheimer Society Research Program (ASRP), Natural Sciences and Engineering Research Council of Canada (NSERC), Fonds de Recherche du Quebec (FRQS), and Douglas Research Centre (DRC). The RADC/ RUSH cohort studies are supported by the National Institutes of Health, National Institute on Aging (R01 AG17917, R01 AG22018, P30 AG10161, and P30 AG72975).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at: https://www.radc.rush.edu/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos